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Abstract
Background: Studies using microarray analysis of colorectal cancer have been generally beleaguered by the lack
of a normal cell population of the same lineage as the tumor cell. One of the main objectives of this study was to
generate a reference gene expression data set for normal colonic epithelium which can be used in comparisons
with diseased tissues, as well as to provide a dataset that could be used as a baseline for studies in alternative
splicing.
Results: We present a dependable expression reference data set for non-neoplastic colonic epithelial cells. An
enriched population of fresh colon epithelial cells were obtained from non-neoplastic, colectomy specimens and
analyzed using Affymetrix GeneChip EXON 1.0 ST arrays. For demonstration purposes, we have compared the data
derived from these cells to a publically available set of tumor and matched normal colon data. This analysis
allowed an assessment of global gene expression alterations and demonstrated that adjacent normal tissues, with
a high degree of cellular heterogeneity, are not always representative of normal cells for comparison to tumors
which arise from the colon epithelium. We also examined alternative splicing events in tumors compared to
normal colon epithelial cells.
Conclusions: The findings from this study represent the first comprehensive expression profile for non-neoplastic
colonic epithelial cells reported. Our analysis of splice variants illustrate that this is a very labor intensive procedure,
requiring vigilant examination of the data. It is projected that the contribution of this set of data derived from pure
colonic epithelial cells will enhance studies in colon-related disease and offer a vital baseline for studies aimed at
elucidating the mechanisms of alternative splicing.
Background
Colorectal cancer (CRC) is considered to develop as a
result of a multi-step progression and accumulation of
genetic alterations [1]. Gene expression profiling using
microarrays has been used extensively in attempts to
identify the genetic events associated with this progres-
sion. For colon cancer, expression profiling can readily
discriminate between tumor and normal tissue as well
as distinguish between tumors of different histopatholo-
gical stage and prognosis to some extent [2,3]. It is
anticipated that the identification of these gene expres-
sion differences may lead to a better understanding of
neoplasia, help identify diagnostic and prognostic
biomarkers, and lead to the discovery of new therapeutic
targets. As with any microarray study, however, tissue
heterogeneity is a confounding factor. Previous studies
on CRC have often used “adjacent normal colon” as a
control cell type. However, this tissue usually represents
a mixture of cell types which do not accurately repre-
sent the epithelial cell lining of the luminal surface of
the colon that gives rise to CRC. Clearly, a comprehen-
sive and representative genee x p r e s s i o np r o f i l ee x c l u -
sively from normal colon epithelial cells would be a
great benefit for comparison with tumor cells, especially
since these cells are not readily cultured.
Here we report a reliable expression reference data set
for non-neoplastic colonic epithelial cells. These cells
were derived from fresh, unfixed, clinically excised non-
tumor related colectomy specimens and enriched using
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body. RNA from these preparations was used to probe
Affymetrix GeneChip® EXON 1.0 ST arrays. These
arrays not only report gene expression levels but can
also identify differential splicing events.
The findings from this study represent the first com-
prehensive expression profile for non-neoplastic colonic
epithelial cells. We have compared the data derived
from these colonic epithelial cells to a publically avail-
able set of tumor and normal matched colon data that
had been hybridized to the same arrays. The dataset is
available from Affymetrix.com http://www.affymetrix.
com/support/technical/sample_data/exon_array_data.
affx. This analysis allowed an assessment of global gene
expression alterations in the tumors and demonstrated
that adjacent normal tissues are not always the optimal
control.
Alternative splicing (AS) is the process by which the
exons of primary transcripts (pre-mRNAs) can be
spliced in different arrangements to produce structurally
and functionally distinct mRNA and protein variants.
Alternative splicing leads to massive diversity by gener-
ating multiple different mRNAs from a single template.
Current estimates indicate that up to 95% of genes in
the human genome exhibit alternative splicing [4].
Furthermore, alternative splicing has increasingly been
acknowledged as critical during normal development.
Previous studies of alternative gene splicing have, for
the most part, focused on the identification and charac-
terization of the control of splice site selection on a
gene-by-gene basis. While these studies have provided
extensive information about the factors and interactions
that control formation of the spliceosome, relatively lit-
tle is known about the global regulatory properties of
alternative splicing [5,6].
In this analysis, we also compared AS events in
tumors and the enriched normal colon epithelial cells.
This analysis of splice variants on a genome-wide scale,
however, is very labor intensive, and requires careful
supervised examination of the data. It is anticipated that
the contribution of this set of data derived from pure
colonic epithelial cells will facilitate future studies in
colon-related disease and offer a unique baseline for stu-
dies aimed at elucidating the mechanisms of alternative
splicing.
Results
One of the main objectives of this study was to generate
a reference gene expression data set for normal colonic
epithelium which can be used in comparisons with
tumor samples. Non-adenomatous and non-neoplastic
colonic epithelial cells were procured from 10 different
colectomy specimens with the clinical indication for
each case being diverticular disease. Of the 10 patients,
6 were female and 4 male, with the ages ranging from
47 to 80 (table 1). The surgeries were performed by 6
different surgeons with four of the specimens excised by
hand assisted laparoscopy and the other 6 performed by
the conventional open surgical approach. The procure-
ment protocol was designed to effectively enrich for the
selected colonic cell population in the shortest time pos-
sible to control for variables that may influence the
quality and integrity of clinical biospecimens, as
described in the Materials and Methods section. The
data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE19163
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE19163
Gene Expression
Twelve samples of isolated colonic epithelial cells from
10 different patients (two of these samples were repli-
cates; see table 1 and figure 1a) were analyzed using the
Exon 1.0 ST arrays. These data were then compared
with a publically available data set http://www.affyme-
trix.com/support/technical/sample_data/exon_array_-
data.affx, [7] which provided raw Exon1.0 ST data for
ten colon tumors and matched ‘normal ‘tissues from the
same patients. Total RNA from these samples were pur-
chased from Biochain Institute Inc. All of the raw data
was imported into PARTEK and the arrays normalized
using quantile normalization followed by probeset sum-
marization using RMA. PCA analysis for these data sets
is shown in figure 1a, where it is evident that the NOR-
MAL and TUMOR tissues from the public data set clus-
tered together, while the CELL samples obtained from
our enrichment procedure separated distinctly from the
two other tissue sources. A3 - w a yA N O V Ai d e n t i f i e d
that a major source of variance was due to the sample
processing differences between the 2 laboratories,
referred to as “SCAN DATE“ (Figure 1b). Patient “SEX“
Table 1 Clinical Correlates of Patient Cohort
Case # Age Sex Location Surgical Approach Diagnosis
1** 55 F Sigmoid Resection Diverticulitis
2 58 M Sigmoid Resection Diverticulosis
3 67 M Sigmoid Laparoscopic Diverticulosis
4** 58 M Sigmoid Laparoscopic Diverticulosis
5 62 M Sigmoid Laparoscopic Diverticulitis
6 80 F Sigmoid Resection Diverticulosis
7 47 F Sigmoid Resection Diverticulosis
8 65 F Sigmoid Resection Diverticulosis
9 62 F Sigmoid Resection Diverticulosis
10 58 F Sigmoid Laparoscopic Diverticultis
Demographics of patients from where the enriched samples of non-neoplastic
colonic epithelial cells were derived. ** Indicate those samples on which
replicates were performed.
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primarily due to the fact that the tumor/normal colon
data set consisted of 5 males and 5 females, while our
analysis used samples from 7 females and 3 males which
slightly skewed the analysis for this category. To correct
for these batch effects, therefore, we removed two of
these sources of variance and reanalyzed the data where
it is clear that the 3 types of tissues now cluster more
closely (Figure 1c) although the CELLs still form a dis-
crete cluster while the TUMOR and NORMAL tissues
cluster together in no defined pattern. Figure 1d displays
the ANOVA histogram showing that the variation attri-
butable to SCAN DATE and SEX have been removed.
Following this corrective processing, the various cut-
off values for expression differences were set at p = 0.05
for the experimental sets compared to normal and com-
bined with fold change values of 2. Genes showing dif-
ferential expression using these analysis parameters are
s h o w ni nt h eV e n nd i a g r a mi nF i g u r e2 .T h i sa n a l y s i s
r e v e a l st h a tt h e r ea r em o r ec h a n g e si nt h ec o m p a r i s o n
between the isolated epithelial cells and the tumor than
there were in the comparison between the matched
tumor and normal tissue. Genes showing the highest
increased expression levels in the tumor vs CELL com-
p a r i s o nw e r eO L F M 4 ,F N 1 ,A C T G 2 ,I G J ,A C T A 2 ,
COL1A2, SPARC, RCN1, COL3A1 and COL1A1. The
genes with the most significant decreases included
TMIGD1, OTOP2, CA4, ZG16, MS4A12, GUCA2B,
BEST4, CD177, HRASLS2, IFIT1 and MUC17.
The data was then analyzed using Ingenuity Pathways
Analysis (IPA version 7.5). One of the top canonical
pathways associated with the DEG list generated from
the comparison of tumor to CELLs was the WNT Sig-
naling Pathway. Fifty eight genes from our analysis of
tumor compared to CELLs were deregulated in this
pathway consisting of 160 members in total (p = 7.81E-
07. The pathway is shown in Additional File 1 and it is
noteworthy that many of the members of this pathway
are up-regulated in tumor tissues. A network generated
from the data analysis is shown in Additional file 2.
This network involves Cancer Cell Cycle, Cellular
Growth and Proliferation functions with an associated
score of 20 (p = 10E-20) and has 35 molecules fitting
into the network. It is apparent from the network ideo-
gram that all molecules interact either directly or indir-
ectly through the CDKN1A gene.
The most significant biological function associated
with disease and disorder category was Cancer with
1126 of the molecules in the comparison of tumors to
epithelial cells fitting into this category with an asso-
ciated p-value of 3.02E-35. The most significantly
altered subcategories within this functional category
included; Tumorigenesis (731 molecules from the DEG
list, p = 3.02E-35), Neoplasia (714 molecules, p = 8.98E-
34), Cancer (691 molecules, p = 3.83E33) Colorectal
Cancer (256 molecules, p = 2.56E-26 and Colon Cancer
(161 molecules, p = 6.10E-25)
The most significant (p = 1.45E-21) molecular and
cellular function was Cell Growth and Proliferation, a
category which describes functions associated with cell
growth including colony formation proliferation and
outgrowth of cells. Six hundred and thirty nine of the
genes from the DEG fit into this cellular function cate-
gory. The most significant (p = 2.47E-11) physiological
function was Tissue Development with 180 genes from
Figure 1 Principle Components Analysis and Analysis of
Variance of Gene Expression Data: The individual genes are
summarized from exon intensities mapping to each locus. The PCA
plot shows data from CELLS (red), NORMAL tissues (blue) and
tumors (green). It can be seen that the tumor and normal tissues
cluster together while the CELLs form a discreet cluster distant from
the other samples. (B) Following a 3-way ANOVA the Sources of
Variation were plotted. It can be seen that “SCAN DATE” is a major
contributer to the variation. This can be attributed to the variation
in processing performed by the 2 different laboratories. Also seen as
a major source of variation is SEX. This is due to the fact that 7 of
the samples in the CELL group were classified as female whereas
the TUMOR/NORMAL set of data had 5 of each sex. (C) The SEX and
SCAN DATE sources of variation were removed from the ANOVA
analysis and the PCA performed. It can be seen that the three
sample types cluster more closely but the CELLs still retain a degree
of separation. (D) shows the ANOVA -Source of Variation histogram
following the removal of the batch effects due to SCAN DATE and
SEX. It is now notable that the major source of variation is due
primarily to the different TISSUE TYPEs.
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category includes functions associated with development
and differentiation and the formation of tissues through
the association of cells including growth, patterning and
survival of tissues, accumulation, adhesion and cluster-
ing of cells.
The comparison of tumor to normal tissue showed
fewer gene expression differences with much lower fold
changes. The highest increases in gene expression
included, LGR5, CST1, SPP1, CLDN1, MMP11, INHBA,
THBS2 SFRP4, ETV4 and SLC6A6. The most signifi-
cantly down-regulated genes included SLC26A3,
GUCA2A, ZG16, CLCA4, MYH11, AQP8, TMIGD1,
CA2, CLCA1, ANPEP and ADH1C.
The most significant (p = 7.69E-07) canonical pathway
associated with the DEG list generated from the com-
parison of tumor to normal tissue was the Hepatic
Fibrosis/Hepatic Stellate Cell Activation Pathway. Inter-
estingly, this was also one of the top 5 pathways found
associated with the tumor vs CELL comparison. Eleven
genes of a possible 126 genes in this canonical pathway
were altered in the comparison between tumor and nor-
mal tissues. This most significant network generated
from this comparison was Cancer, Cell Movement,
Hematological System Development and function. The
score for this network was 16 (p = 10E-16) and is
shown is shown in Additional file 3. It is apparent from
the network ideogram that all molecules interact either
Figure 2 Venn Diagram of gene expression alterations for three comparisons. The tumor vs cell comparison showed the largest number
of transcript expression changes, while the tumor compared to the adjacent normal tissues showed the lowest number. The 77 genes which
show alterations in both the tumor vs cell and tumor vs normal are of interest. All comparisons were performed following RMA normalization of
all raw image files. Following a 3-way ANOVA the sources of variation were removed and the comparisons conducted. Cut-off values for gene
expression differences were p = 0.05 and combined with a > 2-fold change.
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although these genes themselves do not show altered
expression in the tumors compared to normal tissues.
The most significant biological function associated
with disease and disorder category was Cancer and 128
of the molecules in the comparison of tumors to CELLs
fit into this category with an associated p-value of
1.89E-30. The most significant (p = 5.10E-11) molecular
and cellular function was Cellular Movement, 46 of the
genes from the DEG fit into this cellular function cate-
gory. The most significant (p = 4.74E-10) physiological
function was Tissue Morphology with 22 genes from
the DEG list fitting into this functional category. This
category includes functions associated with development
and differentiation and the formation of tissues through
the association of cells including growth, patterning and
survival of tissues, accumulation, adhesion and cluster-
ing of cells.
Thus, from this analysis, it is clear that the altered
gene expression profiles depend on the origin of the
normal sample. Despite the variation in the analysis
between the tumor and different normal samples, 77
genes showed the same changes regardless of the nor-
mal sample used (figure 2). This analysis strategy
demonstrates an important application of this data
because it verifies the gene expression changes that
occur in both isolated cells and hetergenous normal tis-
sue, while omitting the transcript alterations that are
attributable to tissue heterogeneity alone. The genes
showing the highest expression changes in tumor com-
pared to both normal tissues and CELLs were CLDN1,
CST1, KIAA1199, MMP14, RFC3, MTHRD2, ZNF587,
MMP11, INHBA and PSAT1. Genes showing the largest
decreases in expression included; GUCA2A, KPNA7,
S L C 2 6 A 3 ,P L A C 8 ,A N P E P ,S L C 2 6 A 2 ,F A B P 1 ,D H R S 9 ,
SLC4A4 and TSPAN1.
IPA analysis of the data showed that the canonical
pathway with the highest number of members from this
list of 77 overlapping genes was the Bladder Cancer Sig-
naling Pathway with a significance value of p = 9.26E-
06. Only 5 members of the 77 were deregulated in a
pathway consisting of 88 molecules. The WNT Signaling
Pathway was also in the top 5 canonical pathways with a
p value of 1.56E-03. The lower p values in this compari-
son is expected because the list of genes is very limited.
The top network generated from this DEG list is Can-
cer, Cell Growth and Proliferation, Cellular Movement
and is shown in Additional file 4. This pathway has an
associated score of 30 (p = 10E-30). The majority of the
genes showing down-regulation interact with IL8, TNF
and TGFB1, while genes showing increased expression
show direct interactions with HNF1A.
The biological functional analysis showed that the
most significant (p = 5.47E-15) disease and disorder
category generated by this list of 77 overlapping genes
was Cancer. It is noteworthy this was also the most sig-
nificant generated by tumor vs CELL comparison. The
most significant (p = 8.84E-09) molecular function was
Cell Death, a functional category associated with cytoly-
sis, necrosis, survival and recovery of cells. Twenty one
genes from the list of 77 fit into this category, of which
14 demonstrated up-regulation. The most significant (p
= 7.29E-06) physiological function identified was Tissue
Development with 9 molecules fitting in this functional
category. Four of these were involved in the accumula-
tion of cells and were all up-regulated in the tumors. An
additional 3 up-regulated genes were associated with
formation of the endothelial tube and an additional 6
(some genes belong to more than one sub-category)
were associated with cell adhesion.
Exon-Level Analysis
Since the ST arrays not only report gene expression
levels but also splicing differences, we reanalyzed the
data to identify splice variants between the various sam-
ples. A major complication in the analysis of the AS
data, however, comes from the differential detection of
transcription and mRNA processing. If the hybridization
intensities for the individual probesets are examined,
and these differences are used as an index of splicing,
incorrect conclusions will be drawn because the intensi-
ties are not considered within the context of the entire
transcript. As shown in figure 3a, the average intensities
for the probesets representing the exons of the GEM
gene show a high p-value (1.2e-10) for alternative spli-
cing in a comparison between the tumors and CELLs,
but the entire transcript has an overall increased expres-
sion in the tumors compared to the CELLs (average fold
change -5). To overcome this complication, we devised
a more strict way of detecting AS, which was designed
to decrease the false positive rate, although it may also
have eliminated some possible AS events. We also lim-
ited our analysis to a comparison between the tumors
and isolated epithelial cells (CELLs). The exon-specific
probesets required p values for alternative splicing of
<0.0001, the p value for whole transcript expression was
>0.9 and the fold change cut off for whole transcript
expression had to be <2.5 and >-2.5. In this way we
eliminated whole transcript expression while detecting
exon-specific changes and defined 497 genes showing
alternative splicing. Each of these genes was then exam-
ined visually using Partek Genomics Suite gene view.
The full data set is available in Additonal file 5.
To evaluate the utility of our approach, we selected a
subset of genes that were known to be alternatively
spliced as recorded in the UCSC Genome Browser
http://genome.ucsc.edu/. Upon visual examination many
of the genes included in our analysis failed to display
convincing AS events in genes known to be alternatively
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tion of the data. However, we found a number of genes
that displayed convincing alterative splicing in genes
with known AS. Table 2 describes the genes that we
have selected. A few examples of these are shown in fig-
ures 3b, 3c, 3d, 3e and 3f. The average intensities of the
probe sets representing the OSBPL1A gene are shown
in figure 3b. The tumor tissue expresses the full length
isoform B while the CELLs express the truncated iso-
form A version. Another example is shown in Figure 3c
which displays the average intensities for the probesets
representing the exons of the PRKCSH gene. The
tumors express isoform 1 of this gene, while the colon
epithelial cells typify isoform 2. Figure 3d shows that the
overall expression level for PYCARD is higher in the
tumor tissue which expresses the a-isoform of this gene,
while the CELLs clearly express the b isoform. Figure 3e
shows the intensity plot for PHF12 where the tumor
expresses the truncated 3’ exon and the CELLs express
the full length exon. This gene has over 30 different
alternative splice variants recorded. An example of
alterative 5’ exon expression is shown in figure 3f in the
DALRD3 gene.
Of the 497 genes apparently showing alternative splicing,
approximately 60% showed AS events involving exons that
had not been reported in RefSeq. These data demonstrate
the incompleteness of our current understanding of the
extent of AS. For example, (figure 4a) in RefSeq there is
only one representative transcript for the FLOT1 gene
with no alternative splicing. The H-InvDB (Human Full-
length cDNA Annotation Invitational DataBase), released
in December 2008 http://www.h-invitational.jp/hinv/ahg-
db/index.jsp however, describes 7 variants of FLOT1 (Fig-
ure 4a). Interestingly, none of these variants have the same
profile of the patterns shown in figure 4a, where the
tumor appears to have no expression of 5
th and 6
th exons
from the 3’ end of the gene. There are 2 transcripts that
are missing those exons but none that have retained the 5’
exon. Since this gene shows high expression levels, it is
possible that the 5’ p r o b e sc o u l de x c e e dt h es a t u r a t i o n
threshold and therefore the array is not capable of discri-
minating a loss at the 5’ end.
In the same way, the NES gene (figure 4b) apparently
shows differential expression of 2 probe sets in the last 3’
exon and, while RefSeq reports a single variant of this
gene, H-InvDB reports 11 variants. The RefSeq variant is
shown in figure 4b insert in blue. The region on the 3’
exon that shows higher expression in the tumors corre-
sponds to the first and last transcripts reported by H-
InvDB.
Another interesting example is shown in figure 4c
where exons 3, 4 and part of 5 of the C14orf149 gene
appear to be differentially spliced between the two tissue
types. RefSeq details a single transcript for this gene,
while H-Inv reports 4 alternatively spliced variants.
There are currently no known variants that would
explain the differences in the profiles for the two tissues.
Figure 4c shows 10 transcripts reported in H-Inv for the
C20orf149 gene, none of which correspond to the pro-
beset which shows differential splicing between the
colon epithelial cells and the tumor tissues. The circled
transcript closely approximates what is seen on the
array but the actual probeset maps within an expressed
sequence.
In many cases, the probesets would have alternative
splicing events in exons or introns that were not known
Figure 3 Alternative Splicing Events in genes known to have
AS. The grey bars along the top of each diagram represent the
RefSeq gene annotation. Traces in the upper region of each figure
show average intensities of probesets representing exon regions for
tumors (blue) and Cells (red). (a)Shows an example where the
alternative splicing index for the GEM gene has a very low p value
indicating alternative splicing events, however the fold change
values for the entire transcript are ~5 fold suggesting that this is
differential expression (b) The tumor tissue is expressing the full
length isoform B of the OSBPL1A gene, while the cells are
expressing the truncated version, isoform A, which has an
alternative 5’ start. (c) shows a classic example of a cassette exon,
where the tumors are expressing isoform 1 of the PRKCSH gene
and = the colon epithelial cells are representing isoform 2. (d)
demonstrates another example of a cassette exon in the PYCARD
gene. The third exon is not expressed in the tumor (a-isoform) but
is expressed in the cells (b-isoform). (e) shows an example 3’
alternative splicing in the PHF12 gene and (f) displays an example
of a 5’splicing event in the DALRD3 gene.
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genes were reported in RefSeq as AS events. These
examples further highlight the complexity of AS. Figure
5a shows the average intensities for the probesets repre-
senting the exons of the CECR5 gene. The expression
intensities for the last 3 exons are very similar but
values for exons 4 and 5 show higher values for the
tumor. Exon 2 shows similar intensities between the two
tissues and they diverge at the 5’ exon where the CELLs
show an alternative 5’ isoform which has been reported
in RefSeq. The H-InvDB reports 27 alternative splicing
events (Only a few are shown). The arrow shows the
most likely transcript (HIT00075872) whereby the
tumors have retained exons 3 and 4 but the 5’ exon is
missing. The CELLs appear to be expressing the
HIT000279852 transcript that is missing exons 3 and 4
but has retained exons 6 and 7. One caveat with this
scenario is that this transcript also does not express
exon 2. There are differences between the expression of
these two exons between the two tissue types whereby
the tumor has a mean relative intensity of 3.5 and the
CELLs have a mean intensity of 2.9 indicating that this
is the transcript expressed by the CELLs or there is
another variant of this transcript not yet reported.
Figure 5b shows an example of intron retention in the
UBXD5 gene. The tumor appears to be expressing
sequences from the intron between exons 9 and 10.
RefSeq annotates 3 representative transcripts, while H-
InvDB annotates 15 different transcripts but none of
these include retention of this intron. This provides
further evidence that there are more transcripts occur-
ring that are yet to be described. In support of this, a
map of the expressed sequenced tag sites that map to
this region show that a number of ESTs have been
placed in the exact position of the retained intron
shown in the inset of figure 5b.
Clearly, the data obtained from exon array analysis is
very complex and requires in depth analysis of putative
AS events. The availability of this data set which serves
as a normal control in the analysis of colon diseases,
Table 2 Alternatively spliced genes in a comparison of tumors and isolated epithelial cells.
# Probesets Transcript ID Gene Symbol RefSeq Alternative Splicing p-value Fold Change Tumor vs Cell
13 3959350 APOL3 NM_030644 7.20E-11 -1.0483
14 3079463 ABCF2 NM_007189 2.53E-16 -1.0105
14 3082759 DLGAP2 NM_004745 0.0102642 -1.75766
20 3859761 DMKN NM_033317 1.72E-25 -1.00705
33 3132016 FGFR1 NM_023111 0 1.86159
17 4026722 IDH3G NM_174869 3.34E-21 1.37367
12 4027708 MTCP1 NM_001018025 0.000139499 -1.12104
22 2628785 MITF NM_006722 1.62E-27 1.04061
23 3795184 NFATC1 NM_172389 1.05E-19 1.03091
54 3564071 NIN NM_020921 7.07E-13 1.03063
35 2517588 OSBPL6 NM_032523 2.44E-10 -1.26328
40 2858134 PDE4D NM_006203 0 -1.69311
29 3923632 PFKL NM_001002021 0 1.258
12 3751184 PHF12 NM_001033561 8.89E-18 1.09533
19 3821200 PRKCSH NM_001001329 0 -1.0575
9 3688311 PYCARD NM_145182 2.36E-10 1.58277
38 2395245 RERE NM_012102 0 -1.10969
38 2683763 ROBO1 NM_002941 0 2.52196
25 3930360 RUNX1 NM_001754 0 2.48266
14 4007588 SLC35A2 NM_001042498 3.63E-08 -1.01314
23 2428313 ST7L NM_138729 1.59E-42 -1.26644
18 3049025 TBRG4 NM_199122 0.00E+00 2.29256
21 2402601 UBXD5 NM_183008 3.82E-14 1.00668
12 2706791 ZMAT3 NM_152240 1.02E-19 1.5543
The genes were selected by limiting the p-values for alternative splicing to <.0001. To eliminate genes that had whole transcript level differences the p value for
gene expression was set at p > 0.9 and a fold change of <2.5 or >-2.5. The individual probesets for the genes were then visually examined and those with
corresponding reports of alternative splicing events in RefSeq were included in the analysis.
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complex phenomenon of AS.
Discussion
One of the challenges in whole transcript profiling has
been to use the appropriate cell type in comparisons of
tumor to normal CELLs. In this study, we present a
dataset that we feel can serve as a normal control in the
analysis of abnormal colon epithelium at the level of
gene expression, and as a reference for AS profiles using
the Affymetrix Exon1.0 ST arrays. The recent availability
of arrays that allow the detection of AS events on a gen-
ome-wide scale, suggest that detection of gene
expression at the transcript level alone may completely
overlook gene expression changes at the level of splicing
that are germane to the disease state.
The advantage of this particular data set stems from
t h ef a c tt h a tt h ep r o f i l e sa r ederived exclusively from
normal epithelial cells of the colon with no stromal con-
taminants. In colorectal cancer a gradual progression
and accumulation of genetic alterations from the “nor-
mal"/non-neoplastic state to malignancy has been
described. To date, it has not been possible to progres-
sively propagate normal enterocytes in cell culture, mak-
ing gene expression studies difficult [8]. Caco-2 cells
have been used as normal controls for many studies,
Figure 4 AS events without RefSeq Reports. The grey bars along the top of each diagram represent the RefSeq gene annotation. Traces in
the upper region of each figure show average intensities of probesets representing exon regions for tumors (blue) and Cells (red). The lower
insets show extensive annotatation provided by the H-InvDB. RefSeq annotation is shown in blue and ENSEMBL in orange (a) RefSeq annotates
a single transcript for the FLOT1 gene while the H-InvDB reports annotation for 7 variants shown in the inset. None of the additional transcripts
concur with the profile provided by the array. (b) The NES gene shows differential expression of 2 probesets in the 3’ exon. RefSeq reports a
single variant of this gene, H-InvDB reports 11 variants. The region on the 3’ exon that shows higher expression in the tumors corresponds to AS
events in the first and last transcripts (shown by arrows) reported by H-InvDB. (c) The C14orf149 gene appear to be differentially spliced
between the two tissue types at exons 3,4 and part of 5 of. RefSeq details a single transcript for this gene, while H-Inv reports 4 alternatively
spliced variants. None of the reported variants explain the differences between the two tissues profiles obtained from the exon array analysis.
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normal epithelial cells stems from phenotypic similari-
ties to in situ enterocytes based on the acquisition of
structural and functional polarity [9,10] but it has since
been shown that expression characteristics similar to
colon cancer have been observed in these cells [9].
Mucosa from fresh tissue specimens has also been used
as a substitute for normal colonic epithelial cells
[11-17], although microscopic examination of these
samples clearly demonstrates that they represent a
heterogeneous collection of cells with varying propor-
tions of lympocytes scattered from the proximal to distal
end of the colon. Clearly, these cells will compromise
the analysis because of the contribution of the stromal
components. In the latter, there is a preponderance of
fibroblasts, the cells involved in the host’s “desmoplas-
tic” response to the invading tumor.
The approach described here has been previously
proven to enrich for viable, unfixed colonic enterocytes
and profiled them using the Affymetrix GeneChip
Figure 5 Alternative Splicing Events in Exons Other Than Those Reported in RefSeq. The grey bars along the top of each diagram
represent the RefSeq gene annotation. Traces in the upper region of each figure show average intensities of probesets representing exon
regions for tumors (blue) and Cells (red). The lower insets show extensive annotatation provided by the H-InvDB. (a) The trace displays the
average intensities for the probe sets representing the exons of the CECR5 gene. Expression differences are evident v for exons 4 and 5 and
show higher values for the tumor. The 5’ exon also shows differences whereby the CELLs express an alternative 5’ isoform which has been
reported in RefSeq (grey bars). The H-InvDB reports 27 alternative splicing events. The blue arrow highlights the transcript (HIT00075872) the
tumor is expressing with exons 3 and 4 retained but the 5’ exon is missing. The CELLs appear to be expressing a transcript with AS events at
exons 3, 4, 6 and 7 indicated by the red arrow (HIT000279852. (b) The array has a probeset that maps to an intron between exons 9 and 10 in
the UBXD5 gene and this region is retained in the tumor samples. The tumor appears to be expressing sequences from the intron between
exons 9 and 10. RefSeq annotates 3 representative transcripts, while H-InvDB annotates 15 different transcripts but none of these include
retention of this intron. The insert shows a map of the expressed sequenced tag sites ESTs that map to this region on chromosome 1. A
collection of these (delineated by the arrow) have been placed in the exact position of the retained intron on UBXD5.
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Page 9 of 14EXON ST 1.0 array. We used the publicly available
colon paired tumor/normal set to demonstrate the uti-
lity of this data. Analysis at the transcript level allowed
a confirmation of genes that were differentially
expressed between the tumor and normal tissues. This
approach to the analysis of expression data may be an
important application for this data set, as it verifies the
gene expression changes in tissues while omitting
those transcript alterations that are attributable to tis-
sue heterogeneity. Of the 77 genes that showed expres-
sion alterations between the tumors compared to
normal tissues and confirmed in the enterocytes, the
most significant network identified was Cancer, Cell
Growth and Proliferation and Cellular Movement. The
majority of genes show interaction with TNF or
TGFb1 or both. Interestingly, both have been reported
to be involved in the epithelial-mesenchymal transition
(EMT) which characterizes the progression of many
carcinomas, including colon cancer. Bates and Mer-
curio [18] demonstrated that TGFb1-induced EMT is
accelerated dramatically by the presence of activated
macrophages, identified TNF as the critical factor pro-
duced by macrophages that accelerates the EMT in a
model of colon cancer.
The EXON 1.0 ST array does not detect actual tran-
scripts but the expression levels of individual exons,
which are then reconstructed into transcripts virtually.
The analysis does not provide information about which
exons are co-expressed and in which orientation, but
instead assembles genes based on the association of
exons with that particular locus (Affymetrix Technical
Note: Identifying and Validating Alternative Splicing
Events: http://www.affymetrix.com/support/technical/
technotes/id_altsplicingevents_technote.pdf). The com-
mon assumption is that expression levels derived from
these whole-transcript arrays are more accurate predic-
tors of expression. This is due to the fact that 3’ arrays
will typically miscall gene expression alterations in those
genes that have alternative 3’ splicing.
It is perhaps important to appreciate the advantages of
using the Affymetrix GeneChip Exon ST 1.0 arrays and
their ability to define AS. AS introduces several levels of
complexity into the analysis of gene expression altera-
tions, however, several key features have been identified.
AS in a given gene is not an all-or-nothing event, and is
usually a subtle shift in the actual levels of individual
exon expression. Furthermore, error is introduced with
variation in amplification efficiency across individual
transcripts. Bemmo et al [19] suggest that the high GC
content of 5’ end, and reduced priming efficiency in the
3’ end due to an artifact of random priming results in
different signal intensities at the ends of genes and so
increases the number of false positives. This can be
further compounded by tissue heterogeneity and the fact
that splicing patterns can be inherited [20]. Hybridiza-
tion efficiency is also affected by the presence of SNP(s)
within the sequence of the probeset [21]. AS has also
been found to differ as a function of ethnicity [22]. One
commonly used approach to the analysis of Exon array
data is to use the Splicing Index, where the probeset
intensity is divided by the entire transcript intensity
(Affymetrix Technical Note: Identifying and Validating
Alternative SplicingEvents: http://www.affymetrix.com/
support/technical/technotes/id_altsplicingevents_tech-
note.pdf). This approach suffers from some methodolo-
gical and statistical drawbacks resulting in high false
positive rates (see [19] for discussion). We used a very
strict tactic for the detection of AS, to decrease the false
positive rate but this approach may also eliminate possi-
b l eA Se v e n t s .T h eu s eo fA N O V A ,w h e r et h ei n t e r a c -
tion between the sample type and probeset is used to
indicate differential expression of probesets within the
framework of whole transcripts, allows the removal of
variables and permits a calculation of significance of AS
in the absence of large fold changes at the transcript
level. One caveat with this approach is that it assumes
an unvarying response of each probeset within a tran-
script and this assumption is not met for probesets that
are saturated or that hybridize weakly [19]. Using our
stringent criteria for analysis we obtained a list of 497
presumed AS genes, although, upon visual examination
of these genes, very few (~5%) actually exhibited convin-
cing alternative splicing in genes with variants recorded
in RefSeq, highlighting the need for careful examination
of the data produced by such analyses. Most of the AS
changes occurred in genes not reported to be alterna-
tively spliced in RefSeq, and often not reported in more
highly curated databases such as H-InvDB. Due to the
large amount of EST and genomic information, a vast
amount of information can be obtained from in-silico
prediction of transcript isoforms but many of the avail-
able EST libraries are cloned from tumor samples and
as such the databases tend to lack information on nor-
mal splice forms [23].
Conclusions
Use of the Affymetrix GeneChip Exon ST 1.0 and Gene
ST 1.0 arrays will provide an equitable and empirical
platform to access information on transcript variants.
This data set is a valuable asset for studies of colon dis-
ease. We have demonstrated that, using normalization
across array and removal of variation attributed to tech-
nical processing, the data can be compared to tumors
and normal tissue processed at a different time and
place assuring that the data is transportable. The raw
data is available at GEO.
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Sample Processing
Specimen procurement was approved through the
Health Institutional Review Board at the State University
of New York at Buffalo. Specimens were obtained after
surgical removal, and cells obtained from non-diagnos-
tic, excess areas of tissue. Tissue was not collected spe-
cifically for the described research. The samples were
de-identified and the researchers had no contact with
the human subjects.
Briefly, the procurement protocol involved receipt of
the extirpated specimen in the operating suite, rapid
transport to the pathology department, opening and
gross inspection of the specimen and removal of debris
with normal saline washes warmed to body temperature,
followed by exfoliation of cells with the edge of a glass
slide [24]. The exfoliated cells were then placed into a
microcentrifuge tube containing PBS with 10 mM
dithiothreitol (DTT), a mucolytic agent also warmed to
body temperature. During the development of this pro-
curement protocol, elimination of mucus was found to
be necessary to prevent contamination by symbiotic bac-
teria present in the human intestinal tract and other
cells that may have become trapped in the mucus dur-
ing the exfoliation procedure. The groups of cells that
were exfoliated were further dispersed into single and
small groups of cells using a chelating agent (Cellstrip-
per™, Mediatech, Herndon, VA). These washes were
then followed by further enrichment with a red blood
cell lysis agent (RBC Lysis Buffer, eBioscience). Final
enrichment was achieved using magnetic beads coated
with the ber-Ep4 antibody, which recognizes an epitope
previously documented to be expressed in colonic
epithelial cells, which is considered to be specific for
this cell type (Gaffey et al, 1992). The enriched cells
were snap frozen in liquid nitrogen and stored at -80°C.
Total RNA from each sample was extracted within one
month of procurement
To control for variables associated with specimen
integrity and sample processing, the time intervals
between receipt of the sample in the operating suite and
extirpation of each specimen was recorded. Additionally,
the time intervals for delivery to the laboratory, place-
ment of exfoliated cells in PBS with DTT, and the end-
point wherein enriched cells were stabilized by snap
freezing were also documented and presented in table 3.
A portion of the exfoliated cells from one case were
processed in parallel to those procured for microarray
studies, but retained and fixed in 1% glutaraldehyde.
These cells were then concentrated and the pellet used
to generate a cell block, which was processed, sectioned
and then stained for microscopic examination. From
this same colectomy specimen, a small strip of colonic
mucosa was also procured, fixed, processed and stained
for comparative purposes to document cellular hetero-
geneity (figure 6).
Exon Array
The GeneChip® Human Exon 1.0 ST (sense target) array
is a whole-genome array, containing over 1.4 million
probesets of up to four perfect match (PM) probes each,
spread across exons from all known genes, plus a num-
ber of additional regions based on other annotation
sources, including GENSCAN predictions and ESTs
from dbEST. In the design phase, sequences from all the
annotation sources were mapped to the July 2003 ver-
sion of the human genome (UCSC hg16, NCBI 34).
The array contains only PM probes, designed from
NCBI Build 35, with a small number of generic mis-
match probes for background correction. No probes
span exon-exon junctions (Affymetrix Exon Probeset
Annotations White Paper http://www.affymetrix.com/
support/technical/whitepapers/exon_probeset_tran-
s_clust_whitepaper.pdf). Each probeset is assigned to a
‘transcript cluster’, and also has an annotation quality
indicator associated with it.
Using a random hexamer incorporating a T7 promo-
ter, double-stranded cDNA was synthesized from 500
ng total RNA from which the majority of the ribosomal
RNA had been removed using a RiboMinus Human/
Mouse Transcriptome Isolation Kit (Invitrogen, Carls-
bad, CA). cRNA was generated from the double-
stranded cDNA template though an in-vitro transcrip-
tion reaction and purified using the Affymetrix sample
cleanup module. cDNA was regenerated through a ran-
dom-primed reverse transcription using a dNTP mix
Table 3 Sample Processing Variables
Case # TI #1
(min)
TI #2
(min)
TI#3
(min)
TI#4
(min)
TI#5
(min)
1 5324 1 5 1
2 5324 1 5 1
3 3224 2 4 9
4 1274 4 5 4
5 1134 1 4 6
6 1334 1 4 8
7 2224 0 4 6
8 2233 9 4 6
9 2335 2 6 0
1 01224 4 4 9
The procurement protocol sought to enrich the targeted cell population in as
short and consistent time frame to reduce the possibility of introducing
external bias. Time intervals (TI) for the various processing methods of the
collected samples. TI#1: Time interval between extirpation and receipt of
specimen. Differences in times were due to different surgeons. TI#2 Time
interval between receipt of specimen and transit to Department of Pathology.
TI#3 Time interval between opening of the specimen, exfoliation of the cells
and placement into PBS; TI#4 Time interval between placement of cells in PBS
and freezing of cells in liquid nitrogen. TI#5: Time interval summary for the
entire procurement process.
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Ha n dt h ec D N Ap u r i f i e d .T h ec D N Aw a st h e nf r a g -
mented by incubation with a mixture of UDG and APE
1 restriction endonucleases; and end-labeled via a term-
inal transferase reaction incorporating a biotinylated
dideoxynucleotide. 5.5 ug of the fragmented, biotinylated
cDNA was added to a hybridization cocktail, loaded on
a Human Exon 1.0 ST GeneChip and hybridized for 16
hours at 45°C and 60 rpm. Following hybridization, the
array was washed and stained according to the Affyme-
trix protocol. The stained array was scanned at 532 nm
using an Affymetrix GeneChip Scanner 3000, generating
CEL files for each array.
Gene Expression Analysis
Several different comparisons were performed for gene
expression alterations; i) tumor compared to normal tis-
sues from the downloaded data set (TUMOR VS NOR-
MAL), ii) tumor compared to the isolated colon
epithelial cells (TUMOR VS CELLS) and iii) normal
tissue compared to isolated epithelial cells (NORMAL VS
CELLS). Gene expression alterations were determined
using PARTEK Genomics Suite Software. The .CEL files
were imported from the Affymetrix Expression Console
and background correction, normalization and probe
summarization was performed using RMA. Principle
component (PCA) analysis was performed on both sets
of data to examine whether clusters could be explained
by the first few principle components. PCA is used for
dimensionality reduction by retaining the characteristics
of the data that contribute most to its variance.
A gene summarization is then performed on the data
which estimates the intensity of individual genes by aver-
aging the intensities of all the probsets comprising the
gene. The summarization is followed by a 5-way analysis
of variance (ANOVA) using a mixed model and methods
of moment to equate ANOVA mean sum of squares to
their expected values. Due to the fact that each transcript
on the EXON 1.0 ST array has multiple measurements,
Figure 6 Histology of colonic mucosa. (1a) Section of mucosa was stripped off the colectomy specimen and processed by formalin fixation
and paraffin embedding. The mucosa is composed of the lamina propria and epithelium. As is evident, it is not a homogeneous collection of
cells, but rather a composite of the cells that are present in the lamina propria (chronic inflammatory cells, smooth muscle cells and vessels) and
epithelium (hematoxylin and eosin 10×). (1b) Histologic evidence of enrichment for colonic epithelial cells from the procurement approach
described in the text (hematoxylin and eosin 20×).
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of exon-to-exon differences. Other variables included in
this analysis were; scan date, age, sex and tissue type.
Undesired batch effects due to processing from different
laboratories were removed and the data reanalyzed using
a two sample t-test for significance at p = 0.05 and a fold
change cutoff of 2.
To assess the possible functional connections between
the differentially expressed genes (DEGs), a pathways
analysis, which assesses statistically overrepresented
functional terms within a list, was conducted using Inge-
nuity Pathways Analysis (IPA) for all comparisons. The
probability that a specific set of genes has a significant
number of members in a canonical pathway is assigned
a p-value which is calculated by Fisher’s Exact Test
(right tailed). This p-value is based upon the number of
genes in the pathway, the number of focus genes in
each comparison list that belong to the pathway and the
number of corresponding number of genes in each com-
parison that represent inputs. The p-value indicates the
probability of observing the fraction of the focus genes
in the canonical pathway compared to the fraction
expected by chance in the reference set, with the
assumption that each gene is equally likely to be picked
by chance.
IPA generates networks based on the input eligible
molecules in the DEG list. The score is a numerical
value used to rank the generated networks according to
their degree of relevance to the molecules represented
by the DEG list. The score is generated using a right-
tailed Fischer’s Exact test and the score is the negative
log of this p value. Functional analysis of the three DEG
lists was also performed using IPA. This enables an
association of biological functions with the DEG list
using the Ingenuity knowledge database.
Splice Variant Analysis
Exon-level expression values were derived from the CEL
file probe-level hybridization intensities using the
model-based RMA algorithm as implemented in the
Partek Genomics Suite. For this analysis we used the
Core meta-probeset which are the most conservative set
of genes predicted to have the highest confidence score
for transcript clusters. The Core set contains 230,000
exon probesets that have been mapped to 17,800
empirically supported core transcripts.
At w o - w a yA N O V Aw a sp e r f o r m e dt oc o m p a r e
tumors to isolated epithelial cells, with “scan date” as an
ANOVA factor and “tissue type” as the alternative splice
factor. A lack of expression can be mistaken for alterna-
tive splicing because low signals mean that the array
measures experimental noise. For this reason, exons that
were not present in at least one group were removed
from the analysis by restricting the inclusion of probe-
sets to those that have a higher relative signal intensity
of 3. In order to differentiate the exons showing signifi-
cant differences that were alternative splice events from
those that were whole transcripts with significant
expression differences, we assigned an empirically deter-
mined filter such that the exon-specific probesets
required a p value for alternative splicing of <0.0001,
the p value for whole transcript expression was >0.9 and
the fold change cut off for whole transcript expression
was <2 and >-2.. In this way we have eliminated those
exons whose expression changes between the tumor and
normal cells is due to the whole transcript differential
expression. The individual exon expression values were
examined visually in the context of the whole transcript
using Partek Genomics Suite; Gene View. In each of the
reported cases, the exon sequence was “blasted” to
determine if the changes seen could be attributed to
cross hybridization. We also limited our reporting of AS
events to alternatively spliced genes that were recorded
in RefSeq because we had no way to validate the data
and the complexity of this type of data makes it highly
susceptible to false discoveries (see Discussion).
Additional file 1: Wnt-Signaling Pathway Identified by Comparison
of Tumor v Cells. Ingenuity Pathways Analysis of Tumor v Cells
differentially expressed genes (DEG List). IPA identified this canonical
pathway as having a significant number of genes associated with it from
the DEG list. The genes shown in red are up-regulated in the DEG list
and those in green are down-regulated in the DEG list. The more intense
colors represent larger fold change differences. The solid lines between
the molecules indicate the source molecule up-regulates the target
molecule and the dashed lines indicate down-regulation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-5-
S1.JPEG]
Additional file 2: Network Generated by DEG list of Tumor vs Cells.
This network, identified by the tumor vs cell comparison involves Cancer
Cell Cycle, Cellular Growth and Proliferation functions and has a score of
20 (p = 10E-20) and has 35 molecules fitting into the network. It is
apparent from the network ideogram that all molecules interact either
directly or indirectly through the CDKN1A gene. Red indicates increased
expression and green indicates decreased expression. The solid lines
between the molecules indicate the source molecule up-regulates the
target molecule and the dashed lines indicate down-regulation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-5-
S2.JPEG]
Additional file 3: Network Generated by DEG list of Tumor vs
Normal Tissues. This network, identified by the tumor vs normal tissue
comparison involves Cancer, Cell Movement, Hematological System
Development and function. The score for this network was has a score
of 16 (p = 10E-16). It is apparent from the network ideogram that all
molecules interact either directly or indirectly through the TNF or IL1B
genes, although these genes themselves do not show altered expression
in the tumors compared to normal tissues Red indicates increased
expression and green indicates decreased expression. The solid lines
between the molecules indicate the source molecule up-regulates the
target molecule and the dashed lines indicate down-regulation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-5-
S3.JPEG]
Additional file 4: Network Generated by the DEG list of Tumor vs
Cells/Normal Overlap. This network, was identified by the tumor vs cells
and normal tissue comparison (list of 77 genes). The network identified
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Page 13 of 14involves Cancer, Cell Growth and Proliferation, Cellular Movement and
has an associated score of 30 (p = 10E-30). The majority of the genes
showing down-regulation are interacting with IL8, TNF and TGFB1, while
genes showing increased expression show direct interactions with
HNF1A. Red indicates increased expression and green indicates
decreased expression. The solid lines between the molecules indicate the
source molecule up-regulates the target molecule and the dashed lines
indicate down-regulation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-5-
S4.JPEG]
Additional file 5: List of Alternative Splice Events. A strict method of
detecting AS was developed, which was designed to decrease the false
positive rate, although it may also have eliminated some possible AS
events. We also limited our analysis to a comparison between the
tumors and isolated epithelial cells (CELLs). The exon-specific probesets
required p values for alternative splicing of <0.0001, the p value for
whole transcript expression was >0.9 and the fold change cut off for
whole transcript expression had to be <2.5 and >-2.5. In this way we
eliminated whole transcript expression while detecting exon-specific
changes and defined 497 genes showing alternative splicing.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-5-
S5.XLSX]
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